Rankings
▼
Calendar
ARGX
argenx SE
$46B
FY 2022 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$411M
-17.4% YoY
Gross Profit
$381M
92.8% margin
Operating Income
-$720M
-175.4% margin
Net Income
-$710M
-172.8% margin
EPS (Diluted)
$-13.05
Cash Flow
Operating Cash Flow
-$863M
Free Cash Flow
-$967M
Stock-Based Comp.
$157M
Balance Sheet
Total Assets
$3.1B
Total Liabilities
$321M
Stockholders' Equity
$2.8B
Cash & Equivalents
$801M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$411M
$497M
-17.4%
Gross Profit
$381M
$497M
-23.3%
Operating Income
-$720M
-$349M
-106.6%
Net Income
-$710M
-$408M
-74.1%
← Q4 2021
All Quarters
Q2 2022 →
ARGX FY 2022 Earnings — argenx SE Revenue & Financial Results | Market Cap Arena